Statistics for Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial
Total visits
| views | |
|---|---|
| Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial | 66 |
Total visits per month
| views | |
|---|---|
| September 2024 | 0 |
| October 2024 | 0 |
| November 2024 | 0 |
| December 2024 | 0 |
| January 2025 | 0 |
| February 2025 | 0 |
| March 2025 | 0 |
File Visits
| views | |
|---|---|
| nihms-1705876.pdf | 53 |
| java.util.UUID:e661d2ec-f4d1-423c-aced-559e4ca726d6 | 51 |
| java.util.UUID:e35c85d3-a4ab-4958-9cd8-1086abf3131e | 42 |
| java.util.UUID:d6b1a220-0ac9-43ef-aa23-ce9866ae742e | 4 |
Top country views
| views | |
|---|---|
| United States | 51 |
| India | 2 |
| Canada | 1 |
| China | 1 |
| Germany | 1 |
| Italy | 1 |
| Malaysia | 1 |
| Netherlands | 1 |
Top city views
| views | |
|---|---|
| Wilmington | 41 |
| Ann Arbor | 2 |
| Cambridge | 2 |
| Delhi | 2 |
| Beijing | 1 |
| Gunzenhausen | 1 |
| Kansas City | 1 |
| Lake Mary | 1 |
| Las Vegas | 1 |
| Montreal | 1 |
| Orinda | 1 |
| Segrate | 1 |
| Seremban | 1 |
| Washington | 1 |